Last reviewed · How we verify
NCT03928782
Dose-effect Relationship Between microRNAs in Peripheral Blood and Radiation Injury
trial testing 5 Gy or 10 Gy units of whole-body radiation in Radiation Injuries, Experimental in 8 participants. Status unknown.
1 July 2019
Quick facts
| Lead sponsor | Affiliated Hospital to Academy of Military Medical Sciences |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 1 December 2018 |
| Primary completion | 1 July 2019 |
| Estimated completion | 1 September 2019 |
| Sites | 2 locations across China |
Drugs / interventions tested
- 5 Gy or 10 Gy units of whole-body radiation
Conditions studied
- Radiation Injuries, Experimental — all drugs for Radiation Injuries, Experimental →
Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Who can join
Adults 18 to 50, any sex, with Radiation Injuries, Experimental. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rapid and accurate assessment of radiation injury dose is the key to success in early treatment and an urgent issue to be solved in clinical medicine.Researches showed that the expression of the microRNAs in human peripheral blood had much correlation with radiation injury resulted from different dosages of radiation.In this study,acute leukemic patients who will be pretreated by whole-body radiation are taked as the object of study,and biochip technology are adopted to detect the expression levels of the microRNAs in subject peripheral blood before-and-after radiation,and different expression is tested and Bioinformatics prediction,to evaluate the correlation between radiation injury dose and expression levels of the microRNAs in human peripheral blood.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03928782
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Affiliated Hospital to Academy of Military Medical Sciences trials
Trials by the same sponsor.
- NCT06986434 — CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differenti · EARLY_PHASE1 · not yet recruiting
- NCT07416682 — CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms · EARLY_PHASE1 · not yet recruiting
- NCT06834529 — CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma · Phase 1, PHASE2 · recruiting
- NCT06152263 — LCI in Chronic Atrophic Gastritis and Early Gastric Cancer · unknown
- NCT05645601 — CAR-NK Targeted CD19 for r/r B-cell Malignancies · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03928782 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital to Academy of Military Medical Sciences
- Last refreshed: 26 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03928782.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing